SHANGHAI, Nov. 18, 2026 /PRNewswire/ — NeuroGen today announced that AJOVY® (fremanezumab injection), an innovative preventive treatment for adult migraine in-licensed from Teva Pharmaceutical, has officially entered commercial distribution across Chinese Mainland, the initial commercial dispatches simultaneously delivered to many provinces and cities nationwide.
Marking another key milestone following its regulatory approval in June and successful NRDL inclusion[1] last week in November, this launch brings China’s first reimbursement-covered CGRP-targeted therapy directly into clinical practice to benefit the first cohort of migraine patients. As nationwide supply expands alongside the progressive implementation of NRDL coverage next year, AJOVY® is poised to significantly lower treatment barriers, empowering physicians to help more patients achieve scientific, long-term disease management.
Sean Chen, Chief Executive Officer of NeuroGen, said: “By driving global innovation into local care, NeuroGen remains dedicated to serving Chinese patients. With its introduction announced in April this year, fremanezumab injection is not only reshaping the clinical treatment landscape but has also achieved“same-year approval, same-year NRDL inclusion, and simultaneous launch”—completing the entire commercialization cycle in just seven months. Building on this momentum, the successful delivery of its first post-reimbursement batch highlights our strong commercial execution and fulfills our promise to patients. Moving forward, we will leverage our robust network and supply chain to ensure rapid market coverage—bridging the final mile from approval to bedside.”
Migraine is a prevalent and disabling chronic neurological disorder affecting an estimated 100 million people in Chinese Mainland[2], with an annual prevalence rate of 9.3% among adults aged 18 to 65[3]. Characterized by recurrent episodes of moderate-to-severe throbbing headache—often accompanied by nausea, vomiting, photophobia, and phonophobia[4]—migraine substantially impairs patients’ daily functioning, work productivity, and overall quality of life[2]. Many patients also experience comorbid anxiety and depression, underscoring a high unmet demand for disease-specific, preventive therapies[3].
AJOVY® in China:
- 2023– It was approved by the Guangdong Provincial Medical Products Administration, pioneering the “Hong Kong and Macao Medicine and Equipment Connect” policy in the Guangdong-Hong Kong-Macao Greater Bay Area;
- 2024– Fremanezumab met its primary and all secondary endpoints in a China Phase III study, demonstrating efficacy in the Chinese population[5];
- April 2026– NeuroGen entered a strategic partnership with Teva, obtaining exclusive commercialization rights in mainland China[6];
- June 2026– It was approved by the NMPA for the preventive treatment of migraine in adults[7];
- November 2026– Officially included in NRDL[1], benefiting the first cohort of patients in mainland China.
About AJOVY® (Fremanezumab Injection)
AJOVY is an innovative migraine treatment developed by Teva Pharmaceuticals and it offers both monthly (225mg) and quarterly (675mg) subcutaneous dosing options[8]. Among currently marketed anti-CGRP monoclonal antibodies, AJOVY is the only therapy offering these two dosing regimens[9]. The quarterly dosing option significantly reduces injection frequency, helping patients adhere to treatment and sustain long-term control of migraine attacks. The efficacy and safety of AJOVY are supported by multiple clinical studies. A China Phase III study in adult migraine[10] demonstrated a significant reduction in monthly migraine days with a favorable safety profile.
It was first approved in adults by the U.S. Food and Drug Administration (FDA) in 2018[9] and by the European Medicines Agency (EMA) in 2019[9]. In 2025, AJOVY was approved by the FDA for single-dose injection use in children and adolescents aged 6–17 years with episodic migraine weighing 45 kg or more, becoming the world’s first and only CGRP antagonist approved for both pediatric episodic migraine prevention and adult migraine prevention[9].
About NeuroGen
NeuroGen was established in 2024 when Mubadala Investment Company and C-Bridge Capital jointly carved out CNS and Allergy originator portfolios of UCB and its Zhuhai Manufacturing site in China.
Leveraging its end-to-end capabilities covering R&D, manufacturing, and commercialization, NeuroGen focuses on addressing unmet clinical needs in neurology and allergy, with synergistic expansions into pain management. The company is building a scalable, growth-oriented biopharmaceutical platform dedicated to transforming care for better patient outcomes. Visit us at www.neurogen.com.cn to learn more.
References:
- 《国家基本医疗保险、工伤保险和生育保险药品目录(2026年)》.
- Wang YX, et al. J Headache Pain. 2025 May 6;26(1):104.
- 中国医师协会神经内科医师分会, 等. 中国疼痛医学杂志, 2022,28(12)881-898.
- 中华医学会神经病学分会, 等. 中华神经科杂志,2023,56(6):591-613.
- Efficacy Outcomes From a Phase 3, Randomised, Double‑Blind, Placebo‑Controlled Study of Fremanezumab for the Preventive Treatment of Migraine in Chinese Adults[C]. 20th Migraine Trust International Symposium, London, UK, 2024.
- 神基制药官网公告.
- 2026年06月08日药品批准证明文件送达信息.
- 夫瑞奈珠单抗注射液说明书. 2026年06月03日.
- 艾久维®在华获批,灵活给药为偏头痛长期管理带来新选择 https://mp.weixin.qq.com/s/4dmPgbvVKRPhzPhuBQZZ_w
- Yu S, et al. Cephalalgia, 2026, 46(8): 1–13.
ข่าวที่เกี่ยวข้อง
- New global dataset maps where mining and metals intersect with biodiversity
- FITUR 2027 to Expand with Two New Halls, Strengthening Its Commitment to Sustainability and Technology
- ชุดข้อมูลระดับโลกชุดใหม่เผยให้เห็นพื้นที่ที่อุตสาหกรรมเหมืองแร่และโลหะทับซ้อนกับพื้นที่สำคัญต่อความหลากหลายทางชีวภาพ
- MetaOptics Partners with Hong Kong’s ASTRI to Develop a Next-Generation Nano-Optics Imaging System